Top Page
PYC Therapeutics Limited
(Sydney:PYC)
PYC Therapeutics Limited (PYC) vs. S&P 500 (SPY)
PYC Therapeutics Limited Business Overview & Revenue Model
PYC Therapeutics Limited Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 22.06M | 15.81M | 16.04M | 3.07M | 2.40M | Gross Profit |
| 22.06M | 14.92M | 15.20M | 2.45M | 1.85M | EBIT |
| -38.86M | -39.16M | -30.21M | -21.83M | -9.70M | EBITDA |
| -38.12M | -38.25M | -29.39M | -21.04M | -8.89M | Net Income Common Stockholders |
| -37.73M | -22.79M | -13.86M | -17.77M | -6.82M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 66.87M | 15.57M | 29.11M | 51.50M | 25.43M | Total Assets |
| 91.24M | 37.17M | 45.35M | 57.94M | 31.55M | Total Debt |
| 1.11M | 315.49K | 943.77K | 730.35K | 798.14K | Net Debt |
| -65.76M | -15.26M | -28.17M | -17.70M | -6.44M | Total Liabilities |
| 10.18M | 8.72M | 5.15M | 4.02M | 1.35M | Stockholders Equity |
| 80.50M | 27.75M | 39.35M | 53.04M | 28.45M |
| Cash Flow | Free Cash Flow | |||
| -38.90M | -24.91M | -22.17M | -12.38M | -5.85M | Operating Cash Flow |
| -38.59M | -24.42M | -21.78M | -11.79M | -5.75M | Investing Cash Flow |
| -307.04K | -477.12K | 32.68M | -15.52M | -13.77M | Financing Cash Flow |
| 90.19M | 11.44M | -182.36K | 38.56M | 25.11M |
PYC Therapeutics Limited Technical Analysis
PYC Therapeutics Limited Peers Comparison
PYC Therapeutics Limited Corporate Events
PYC Therapeutics has made significant progress in Q1 2025 towards becoming a commercial-stage drug developer, extending its cash runway to over $200 million through a $146 million Entitlement Offer. This funding supports the advancement of its drug candidates, including human trials for polycystic kidney disease and ongoing studies in Retinitis Pigmentosa, positioning the company for improved market conditions and stakeholder confidence.
PYC Therapeutics Limited has announced the application for the quotation of 32,313,759 ordinary fully paid securities on the Australian Securities Exchange (ASX), with the issue date set for April 24, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning and providing opportunities for stakeholders.
PYC Therapeutics Limited has successfully completed its Entitlement Offer, raising approximately $146 million, which contributes to a cash runway exceeding $200 million. This financial boost will support the company in advancing its pipeline of first-in-class drug candidates, with human safety and efficacy read-outs expected over the next 24 months, potentially strengthening its position in the precision medicine industry.
PYC Therapeutics Limited has announced the dosing of the first subject in its Phase 1a clinical trial for PYC-003, a drug candidate aimed at treating Polycystic Kidney Disease (PKD). This trial marks a significant step in addressing PKD, a condition with no current treatment options, and if successful, could lead to a rapid approval process following a combined Phase 2/3 study. The trial will assess the safety and efficacy of PYC-003, with plans to escalate dosing and expand the study to include patients with PKD later in 2025.
PYC Therapeutics Limited announced progress in its ~$146 million Entitlement Offer, having secured ~$133 million so far, which extends its cash runway to over $200 million. However, the underwriter for the remaining ~$13 million has requested an extension due to liquidity issues, prompting PYC to seek payment guarantees and a bond to mitigate potential risks, which could impact the company’s financial stability and stakeholder confidence.
PYC Therapeutics Limited has released a presentation to update investors on its business progress. The presentation, intended as an aid, emphasizes the company’s ongoing commitment to advancing its therapeutic developments. However, it advises caution regarding forward-looking statements due to potential risks and uncertainties that could impact future outcomes.
PYC Therapeutics Limited has successfully raised $9.3 million through the retail component of its Accelerated Non-Renounceable Entitlement Offer, contributing to a total of approximately $100 million raised so far. The total funding goal of $146 million will enable PYC to advance its pipeline of four first-in-class drug candidates with disease-modifying potential, addressing areas of major unmet patient need. This financial boost is expected to significantly impact PYC’s operations by facilitating multiple human efficacy read-outs, potentially enhancing its position within the rapidly growing RNA therapeutic industry.
PYC Therapeutics has released its Appendix 4D and interim financial statements for the period ending 31 December 2024. This announcement, authorized by the company’s board, highlights PYC’s ongoing efforts in the RNA therapeutic sector, emphasizing its commitment to advancing treatments for genetic disorders. The release may impact the company’s operations by reinforcing its position in the biotechnology industry and providing stakeholders with updated financial insights.
PYC Therapeutics Limited announced the quotation of 72,984,880 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to enhance the company’s market presence and provide additional capital for its ongoing research and development efforts.
PYC Therapeutics Limited announced a pro-rata accelerated non-renounceable entitlement offer to raise capital through the issuance of new shares. The offer, which consists of both institutional and retail components, aims to raise a total of approximately $146 million before costs. This capital raising initiative is expected to strengthen the company’s financial position as it continues to advance its drug development programs.
PYC Therapeutics Limited announced the dispatch of the Retail Offer Booklet for its accelerated non-renounceable entitlement offer, which was previously revealed to the Australian Securities Exchange (ASX). The retail component of this offer is now open, allowing eligible shareholders to purchase new shares at a set price. This initiative is part of PYC’s strategy to strengthen its financial base, which is crucial for advancing its RNA therapy projects and maintaining its competitive edge in the biotechnology industry.
PYC Therapeutics Limited has launched a 1 for 4 accelerated non-renounceable pro-rata entitlement offer of fully paid ordinary shares, priced at $1.25 per share. This initiative is part of their strategy to strengthen their financial position and support future growth. The offer is accessible to eligible retail shareholders in Australia and New Zealand, while excluding the United States, reflecting the company’s focus on expanding its shareholder base within these regions.
PYC Therapeutics Limited has successfully completed the institutional component of its Entitlement Offer, raising approximately $91 million, with the total expected to reach $146 million upon the completion of the Retail Entitlement Offer. This funding will enable PYC to advance its pipeline of four first-in-class drug candidates aimed at addressing significant unmet medical needs, with human data read-outs anticipated over the next 24 months, potentially impacting its operations and market positioning significantly.
PYC Therapeutics Limited has announced a pro-rata accelerated non-renounceable entitlement offer to raise up to A$145.8 million. This fundraising initiative is set to enhance the company’s financial stability and support its strategic growth plans. The offer comprises an institutional and a retail component, with a ‘top-up’ facility allowing eligible retail shareholders to apply for additional shares. The retail component is underwritten for $70 million by a group of underwriters, ensuring financial backing. This move is anticipated to significantly impact the company’s capital structure and provide resources for ongoing and future projects, potentially influencing its market position and stakeholder interests.
PYC Therapeutics Limited has announced an accelerated non-renounceable entitlement offer, proposing to issue up to 116,651,930 ordinary fully paid securities. This initiative is part of the company’s strategy to enhance its capital structure and support its ongoing development programs, potentially strengthening its position in the biotechnology industry and offering significant implications for its stakeholders.
PYC Therapeutics Limited announced a pro-rata accelerated non-renounceable entitlement offer of new shares to its eligible institutional and retail shareholders. This equity raising initiative is intended to strengthen the company’s financial position and support its ongoing operations, potentially enhancing its competitive standing in the biotechnology sector.
PYC Therapeutics Limited has announced a plan to raise up to approximately $146 million through an accelerated non-renounceable entitlement offer. The funds will be used to support the progression of its drug pipeline through critical human trials, with all four programs expected to be funded through FY27. This move, backed by key shareholder support and underwriting agreements, is expected to strengthen PYC’s position in the biotechnology sector by enabling the advancement of its innovative treatments for blinding eye diseases.
PYC Therapeutics Limited has announced a trading halt on its securities pending an announcement regarding a proposed capital raising. This decision is expected to impact the company’s market activity, with the trading halt lifted by February 19, 2025, following the release of the announcement. The move indicates strategic financial planning aimed at furthering the company’s development efforts in its target therapeutic areas.
PYC Therapeutics has received regulatory approval to begin human trials for its PKD drug candidate, PYC-003. The trials will start with a Single Ascending Dose study involving healthy volunteers and PKD patients in Australia, aiming to generate initial safety and efficacy data by 2025. This development marks a significant step in addressing the unmet medical need for PKD treatments and could enhance PYC’s position in the biotechnology industry.